These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 19108005)
1. Therapy for portal hypertension: What is our pipeline? Shah V Hepatology; 2009 Jan; 49(1):4-5. PubMed ID: 19108005 [No Abstract] [Full Text] [Related]
2. Hemodynamic changes in splanchnic blood vessels in portal hypertension. Colle I; Geerts AM; Van Steenkiste C; Van Vlierberghe H Anat Rec (Hoboken); 2008 Jun; 291(6):699-713. PubMed ID: 18484617 [TBL] [Abstract][Full Text] [Related]
4. The relationship between liver function and portal pressure: what comes first, the chicken or the egg? Triantos C; Samonakis D; Thalheimer U; Patch D; Burroughs A J Hepatol; 2005 Jan; 42(1):146-7; author reply 147-8. PubMed ID: 15629521 [No Abstract] [Full Text] [Related]
5. Vagal mediation of systemic cardiovascular response to portal hypertension: from experimental studies in animals to treatment of humans. Møller S Gut; 2008 Jul; 57(7):884-5. PubMed ID: 18559383 [No Abstract] [Full Text] [Related]
6. [A new view on angiogenesis and effect of dearterialization of the liver in the surgery of portal hypertension and oncohepatology]. Kashchenko VA Vestn Khir Im I I Grek; 2003; 162(2):114-6. PubMed ID: 14606165 [No Abstract] [Full Text] [Related]
7. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. Langer DA; Shah VH J Hepatol; 2006 Jan; 44(1):209-16. PubMed ID: 16297493 [No Abstract] [Full Text] [Related]
8. Coronary vascular development. Gittenberger-de Groot AC; Lie-Venema H; van den Akker NM; Winter EM; Poelmann RE Wien Klin Wochenschr; 2007; 119(11-12 Suppl 1):4-5. PubMed ID: 19618587 [No Abstract] [Full Text] [Related]
10. [Role of biologically active agents in the pathogenesis of proliferative vitreoretinopathy]. Boĭko EV; Roshkius VP Vestn Oftalmol; 2008; 124(6):51-3. PubMed ID: 19205405 [No Abstract] [Full Text] [Related]
11. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor. Shibuya M FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy of lisinopril and nebivolol therapy of portal hypertension and kidney dysfunction in patients with liver cirrhosis]. Fedulenkova LV; Drozdov VN; Mikheeva OM; Petrakov AV Eksp Klin Gastroenterol; 2008; (5):37-41. PubMed ID: 19145915 [No Abstract] [Full Text] [Related]
13. Surgical therapy for portal hypertension in patients with cirrhosis in China: present situation and prospects. Zhou GW; Li HW Chin Med J (Engl); 2009 Jul; 122(13):1483-5. PubMed ID: 19719933 [No Abstract] [Full Text] [Related]
14. Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes. Nam DH; Oh J; Roh JH; Huh K Ophthalmologica; 2009; 223(3):188-91. PubMed ID: 19182495 [TBL] [Abstract][Full Text] [Related]